Ambit Biosciences Cuts IPO Price
5/16/2013 8:02:57 AM
More...
|
San Diego's Receptos, Ambit Biosciences, Get Ready for IPO Debuts
5/7/2013 7:52:32 AM
More...
|
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
4/15/2013 6:40:36 AM
More...
|
Astellas Pharma Inc. (YPH.BE) and Ambit Biosciences to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
3/12/2013 6:48:51 AM
More...
|
Ambit Biosciences Refiles for a $58 Million IPO
2/21/2013 7:58:55 AM
More...
|
Ambit Biosciences and Astellas Pharma Inc. (YPH.BE) Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
12/11/2012 9:15:39 AM
More...
|
Stunning Data for Ambit Biosciences/Astellas Pharma Inc. (YPH.BE) AML Drug
12/10/2012 8:18:52 AM
More...
|
Astellas Pharma Inc. (YPH.BE) and Ambit Biosciences Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
11/6/2012 12:05:28 PM
More...
|
Insiders Commit $50 Million to Ambit Biosciences
11/6/2012 8:02:38 AM
More...
|
Ambit Biosciences and Teva Pharmaceutical Industries Limited (TEVA) Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
5/17/2012 11:26:14 AM
More...
|
|